The crosstalk between cytokines and immunoglobulin G (IgG) N-glycosylation forms a bidirectional regulatory network that significantly impacts inflammation and immune function. This review examines how various cytokines, both pro- and anti-inflammatory, modulate IgG N-glycosylation, shaping antibody activity and influencing inflammatory responses. In addition, we explore how altered IgG N-glycosylation patterns affect cytokine production and immune signaling, either promoting or reducing inflammation. Through a comprehensive analysis of current studies, this review underscores the dynamic relationship between cytokines and IgG N-glycosylation. These insights enhance our understanding of the mechanisms underlying inflammatory diseases and contribute to improved strategies for disease prevention, diagnosis, monitoring, prognosis, and the exploration of novel treatment options. By focusing on this crosstalk, we identify new avenues for developing innovative diagnostic tools and therapies to improve patient outcomes in inflammatory diseases.
Get full access to this article
View all access options for this article.
References
1.
AlbertH, CollinM, DudziakD, et al.In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A, 2008; 105(39):15005–15009; doi: 10.1073/pnas.0808248105
2.
AliyuM, ZohoraFT, AnkaAU, et al.Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol, 2022; 111:109130; doi: 10.1016/j.intimp.2022.109130
3.
AlterG, OttenhoffTHM, JoostenSA. Antibody glycosylation in inflammation, disease and vaccination. Semin Immunol, 2018; 39:102–110; doi: 10.1016/j.smim.2018.05.003
4.
AnthonyRM, KobayashiT, WermelingF, et al.Intravenous gammaglobulin suppresses inflammation through a novel T H 2 pathway. Nature, 2011; 475(7354):110–113; doi: 10.1038/nature10134
5.
ArnoldJN, WormaldMR, SimRB, et al.The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol, 2007; 25(1):21–50; doi: 10.1146/annurev.immunol.25.022106.141702
6.
BartschYC, EschweilerS, LeliavskiA, et al.IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants. J Allergy Clin Immunol, 2020; 146(3):652–666.e11; doi: 10.1016/j.jaci.2020.04.059
7.
BartschYC, RahmöllerJ, MertesMMM, et al.Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of lupus nephritis and rheumatoid arthritis. Front Immunol, 2018; 9:1183; doi: 10.3389/fimmu.2018.01183
8.
BasM, TerrierA, JacqueE, et al.Fc sialylation prolongs serum half-life of therapeutic antibodies. J Immunol, 2019; 202(5):1582–1594; doi: 10.4049/jimmunol.1800896
9.
BaumannI, KolowosW, VollRE, et al.Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2002; 46(1):191–201; doi: 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K
10.
BenedenKV, CoppietersK, LaroyW, et al.Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis, 2009; 68(8):1360–1365; doi: 10.1136/ard.2008.089292
11.
BoshtamM, AsgaryS, KouhpayehS, et al.Aptamers against pro- and anti-inflammatory cytokines: A review. Inflammation, 2017; 40(1):340–349; doi: 10.1007/s10753-016-0477-1
12.
BossenC, SchneiderP. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol, 2006; 18(5):263–275; doi: 10.1016/j.smim.2006.04.006
13.
BraunJ, BollowM, NeureL, et al.Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum, 1995; 38(4):499–505; doi: 10.1002/art.1780380407
14.
BugdaciMS, KaracaC, KoksalAR, et al.The association with histopathological findings and predictive significance of transforming growth factor beta 1 (TGF Β1) in patients with chronic viral hepatitis. Archives Hepatitis Res, 2023; 9(1):5–10.
15.
BuhreJS, PongraczT, GeisenUM, et al.Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination. Allergy, 2024; 00:1–17; doi: 10.1111/all.16241
16.
CaoY, SongZ, GongY, et al.The immune microenvironment of Hashimoto’s thyroiditis regulates the glycosylation modification of IgG. J Endocr Soc, 2021; 5(Supplement_1):A845–A845; doi: 2021071002205768400
17.
CaoY, SongZ, GuoZ, et al.Cytokines in the immune microenvironment change the glycosylation of IgG by regulating intracellular glycosyltransferases. Front Immunol, 2022; 12:724379; doi: 10.3389/fimmu.2021.724379
18.
CelisR, CuervoA, RamírezJ, et al.Psoriatic synovitis: Singularity and potential clinical implications. Front Med (Lausanne), 2019; 6:14; doi: 10.3389/fmed.2019.00014
19.
ChakrabortyS, GonzalezJ, EdwardsK, et al.Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol, 2021; 22(1):67–73; doi: 10.1038/s41590-020-00828-7
20.
ChauhanP, NairA, PatidarA, et al.A primer on cytokines. Cytokine, 2021; 145:155458; doi: 10.1016/j.cyto.2021.155458
21.
ChoyEHS, PanayiGS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 2001; 344(12):907–916; doi: 10.1056/nejm200103223441207
22.
ChuVT, EnghardP, RiemekastenG, et al.In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol, 2007; 179(9):5947–5957; doi: 10.4049/jimmunol.179.9.5947
23.
ChungAW, CrispinM, PritchardL, et al.Identification of antibody glycosylation structures that predict monoclonal antibody Fc-Effector function. AIDS, 2014; 28(17):2523–2530; doi: 10.1097/QAD.0000000000000444
24.
CiccheseJM, EvansS, HultC, et al.Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev, 2018; 285(1):147–167; doi: 10.1111/imr.12671
25.
ClauderAK, KordowskiA, BartschYC, et al.IgG Fc N-glycosylation translates MHCII haplotype into autoimmune skin disease. J Invest Dermatol, 2021; 141(2):285–294; doi: 10.1016/j.jid.2020.06.022
26.
CollinM, OlsénA. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. Embo J, 2001; 20(12):3046–3055; doi: 10.1093/emboj/20.12.3046
27.
CollinsES, GalliganMC, SaldovaR, et al.Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford), 2013; 52(9):1572–1582; doi: 10.1093/rheumatology/ket189
28.
CroceA, FiruziO, AltieriF, et al.Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal, 2007; 21(5):303–314; doi: 10.1002/jcla.20191
29.
DavidsonA. BAFF and APRIL and their receptors. In: Encyclopedia of Medical Immunology: Autoimmune Diseases. (MackayIan R and RoseNR and DB and DA. eds.) Springer New York: New York, NY; 2014; pp. 181–187; doi: 10.1007/978-0-387-84828-0_563
30.
DelgadoME, BrunnerT. The many faces of tumor necrosis factor signaling in the intestinal epithelium. Genes Immun, 2019; 20(8):609–626; doi: 10.1038/s41435-019-0057-0
31.
DengZ, FanT, XiaoC, et al.TGF-β signaling in health, disease, and therapeutics. Signal Transduct Target Ther, 2024; 9(1):61; doi: 10.1038/s41392-024-01764-w
32.
DostertC, GrusdatM, LetellierE, et al.The TNF family of ligands and receptors: Communication modules in the immune system and beyond. Physiol Rev, 2019; 99(1):115–160; doi: 10.1152/physrev.00045.2017
ErcanA, CuiJ, ChattertonDEW, et al.Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum, 2010; 62(8):2239–2248; doi: 10.1002/art.27533
35.
ErcanA, CuiJ, HazenMM, et al.Hypogalactosylation of serum N-Glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther, 2012; 14(2):R43; doi: 10.1186/ar3756
36.
FujitaT. Evolution of the Lectin - Complement pathway and its role in innate immunity. Nat Rev Immunol, 2002; 2(5):346–353; doi: 10.1038/nri800
37.
FurmanD, CampisiJ, VerdinE, et al.Chronic inflammation in the etiology of disease across the life span. Nat Med, 2019; 25(12):1822–1832; doi: 10.1038/s41591-019-0675-0
38.
GaoS, JiaoX, GuoR, et al.Reduced serum IgG galactosylation is associated with increased inflammation during relapses of neuromyelitis optica spectrum disorders. Front Immunol, 2024; 15:1357475; doi: 10.3389/fimmu.2024.1357475
39.
GironLB, ColombF, PapasavvasE, et al.Interferon-α alters host glycosylation machinery during treated HIV infection. EBioMedicine, 2020; 59:102945; doi: 10.1016/j.ebiom.2020.102945
40.
GoetzeAM, LiuYD, ZhangZ, et al.High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology, 2011; 21(7):949–959; doi: 10.1093/glycob/cwr027
41.
GudeljI, LaucG, PezerM. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol, 2018; 333:65–79; doi: 10.1016/j.cellimm.2018.07.009
42.
GyebrovszkiB, ÁcsA, SzabóD, et al.The role of IgG Fc region N-Glycosylation in the pathomechanism of rheumatoid arthritis. IJMS, 2022; 23(10):5828; doi: 10.3390/ijms23105828
43.
HanJ, GongGZ, LeiJH, et al.Response to immune complex vaccine in chronic hepatitis B patients is associated with lower baseline level of serum IgG galactosylation. Medicine (Baltimore), 2019; 98(26):e16208; doi: 10.1097/MD.0000000000016208
44.
HanićM, VučkovićF, DerišH, et al.PANTS Consortium.. Anti-TNF biologicals enhance the anti-inflammatory properties of IgG N-Glycome in Crohn’s disease. Biomolecules, 2023; 13(6); doi: 10.3390/biom13060954
45.
HitsumotoY, ThompsonSJ, ZhangYW, et al.Relationship between interleukin 6, agalactosyl IgG and pristane-induced arthritis. Autoimmunity, 1992; 11(4):247–254; doi: 10.3109/08916939209035162
HoCH, ChienRN, ChengPN, et al.Association of serum IgG N-Glycome and transforming growth factor-Β1 with hepatitis B virus e antigen seroconversion during entecavir therapy. Antiviral Res, 2014; 111:121–128; doi: 10.1016/j.antiviral.2014.09.011
48.
HoepelW, ChenHJ, GeyerCE, et al.High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med, 2021; 13(596); doi: 10.1126/scitranslmed.abf8654
49.
JangDI, LeeAH, ShinHY, et al.The role of tumor necrosis factor alpha (Tnf-α) in autoimmune disease and current Tnf-α inhibitors in therapeutics. Int J Mol Sci, 2021; 22(5); doi: 10.3390/ijms22052719
50.
JeddiP, KeuschJ, LydyardPM, et al.The effect on immunoglobulin glycosylation of altering in Vivo production of immunoglobulin G. Immunology, 1999; 98(3):475–480; doi: 10.1046/j.1365-2567.1999.00896.x
51.
JenneweinMF, AlterG. The immunoregulatory roles of antibody glycosylation. Trends Immunol, 2017; 38(5):358–372; doi: 10.1016/j.it.2017.02.004
52.
KantoN, OhkawaY, KitanoM, et al.A highly specific antibody against the core fucose of the N-Glycan in IgG identifies the pulmonary diseases and its regulation by CCL2. J Biol Chem, 2023; 299(12):105365; doi: 10.1016/j.jbc.2023.105365
53.
KuhnsS, ShuJ, XiangC, et al.Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic monoclonal antibodies. J Biotechnol, 2020; 317:5–15; doi: 10.1016/j.jbiotec.2020.04.017
54.
KyburzD, CorrM. Th17 cells generated in the absence of TGF-β induce experimental allergic encephalitis upon adoptive transfer. Expert Rev Clin Immunol, 2011; 7(3):283–285; doi: 10.1586/eci.11.7
55.
LarsenMD, de GraafEL, SonneveldME, et al.biobank study group.. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science, 2021; 371(6532); doi: 10.1126/science.abc8378
56.
LaucG, HuffmanJE, PučićM, et al.Loci associated with N-Glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet, 2013; 9(1):e1003225; doi: 10.1371/journal.pgen.1003225
57.
LeonardWJ, LinJX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov, 2023; 22(10):827–854; doi: 10.1038/s41573-023-00746-x
58.
LiuC, ChuD, Kalantar-ZadehK, et al.Cytokines: From clinical significance to quantification. Adv Sci (Weinh), 2021; 8(15):e2004433; doi: 10.1002/advs.202004433
59.
LiuD, LiQ, ZhangX, et al.Systematic review: Immunoglobulin G N-Glycans as next-generation diagnostic biomarkers for common chronic diseases. OMICS, 2019a;23(12):607–614; doi: 10.1089/omi.2019.0032
60.
LiuP, WangX, DunA, et al.High-throughput profiling of serological immunoglobulin G N-glycome as a noninvasive biomarker of gastrointestinal cancers. Engineering, 2023; 26:44–53; doi: 10.1016/j.eng.2023.02.008
61.
LiuJ, ZhuQ, HanJ, et al.IgG galactosylation status combined with MYOM2-Rs2294066 precisely predicts anti-TNF response in Ankylosing Spondylitis. Mol Med, 2019b;25(1):25; doi: 10.1186/s10020-019-0093-2
62.
LoodC, AllhornM, LoodR, et al.IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: A possible new treatment? Arthritis Rheum, 2012; 64(8):2698–2706; doi: 10.1002/art.34454
63.
MagorivskaI, MuñozLE, JankoC, et al.Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells. Clin Exp Immunol, 2016; 184(1):110–117; doi: 10.1111/cei.12744
64.
MarkovicsA, RosenthalKS, MikeczK, et al.Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: New insights from animal models. Biomedicines, 2021; 10(1); doi: 10.3390/biomedicines10010044
65.
MartinTC, IlievaKM, ViscontiA, et al.Dysregulated antibody, natural killer cell and immune mediator profiles in autoimmune thyroid diseases. Cells, 2020; 9(3); doi: 10.3390/cells9030665
66.
MedzhitovR. The spectrum of inflammatory responses. Science, 2021; 374(6571):1070–1075; doi: 10.1126/science.abi5200
67.
MillerMC, MayoKH. Chemokines from a structural perspective. Int J Mol Sci, 2017; 18(10); doi: 10.3390/ijms18102088
68.
NakayamadaS, TanakaY. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen, 2016; 36(1):6; doi: 10.1186/s41232-016-0015-4
69.
NandakumarKS, CollinM, HapponenKE, et al.Streptococcal endo-β-N-acetylglucosaminidase suppresses antibody-mediated inflammation in vivo. Front Immunol, 2018; 9:1623; doi: 10.3389/fimmu.2018.01623
70.
NandakumarKS, CollinM, OlsénA, et al.Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG Glycosylation in arthritis. Eur J Immunol, 2007; 37(10):2973–2982; doi: 10.1002/eji.200737581
71.
NguyenTHO, RowntreeLC, ChuaBY, et al.Defining the balance between optimal immunity and immunopathology in influenza virus infection. Nat Rev Immunol, 2024; 24(10):720–735; doi: 10.1038/s41577-024-01029-1
72.
NimmerjahnF, AnthonyRM, RavetchJV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A, 2007; 104(20):8433–8437; doi: 10.1073/pnas.0702936104
73.
NimmerjahnF, VidarssonG, CraggMS. Effect of posttranslational modifications and subclass on IgG activity: From immunity to immunotherapy. Nat Immunol, 2023; 24(8):1244–1255; doi: 10.1038/s41590-023-01544-8
74.
OppenheimJJ. Cytokines, their receptors and signals. In: The Autoimmune Diseases. Elsevier; 2020; pp. 275–289; doi: 10.1016/B978-0-12-812102-3.00015-4
75.
PasekM, DukM, PodbielskaM, et al.Galactosylation of IgG from rheumatoid arthritis (RA) patients - changes during therapy. Glycoconj J, 2006; 23(7–8):463–471; doi: 10.1007/s10719-006-5409-0
76.
PeršeM, UnkovičA. The role of TNF in the pathogenesis of inflammatory bowel disease. In: Biological Therapy for Inflammatory Bowel Disease. Drugs, 2020; doi: 10.5772/intechopen.84375
77.
PfeifleR, KittlerJ, WuhrerM, et al.AB0016 the impact of IL-17A therapy on IGG sialylation in humans. Ann Rheum Dis, 2021; 80(Suppl 1):1042.1–1043; doi: 10.1136/annrheumdis-2021-eular.1087
78.
PfeifleR, RotheT, IpseizN, et al.Regulation of autoantibody activity by the IL-23-T H 17 axis determines the onset of autoimmune disease. Nat Immunol, 2017; 18(1):104–113; doi: 10.1038/ni.3579
79.
Prieto-PeñaD, GenreF, Remuzgo-MartínezS, et al.BAFF, APRIL and BAFFR on the pathogenesis of immunoglobulin-A vasculitis. Sci Rep, 2021; 11(1):16946; doi: 10.1038/s41598-021-91055-z
80.
PučićM, KneževićA, VidičJ, et al.High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Molecular and Cellular Proteomics, 2011; 10(10):M111.010090; doi: 10.1074/mcp.M111.010090
81.
QuastI, KellerCW, MaurerMA, et al.Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest, 2015; 125(11):4160–4170; doi: 10.1172/JCI82695
82.
RajuTS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol, 2008; 20(4):471–478; doi: 10.1016/j.coi.2008.06.007
83.
RaulfMK, LepeniesB. Glycosylation tips the scales: Novel insights into the dual role of type-I interferons in treated HIV infection. EBioMedicine, 2020; 60:103003; doi: 10.1016/j.ebiom.2020.103003
84.
RussellA, AduaE, UgrinaI, et al.Unravelling immunoglobulin G Fc N-glycosylation: A dynamic marker potentiating predictive, preventive and personalised medicine. International Journal of Molecular Sciences, 2018; 19(2); doi: 10.3390/ijms19020390
85.
ScallonBJ, TamSH, McCarthySG, et al.Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol, 2007; 44(7):1524–1534; doi: 10.1016/j.molimm.2006.09.005
86.
ScanlanCN, BurtonDR, DwekRA. Making autoantibodies safe. Proc Natl Acad Sci U S A, 2008; 105(11):4081–4082; doi: 10.1073/pnas.0801192105
87.
SchinoccaC, RizzoC, FasanoS, et al.Role of the IL-23/IL-17 pathway in rheumatic diseases: An overview. Front Immunol, 2021; 12:637829; doi: 10.3389/fimmu.2021.637829
88.
SchwabI, NimmerjahnF. Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol, 2013; 13(3):176–189; doi: 10.1038/nri3401
89.
ShabgahAG, Shariati-SarabiZ, Tavakkol-AfshariJ, et al.The role of BAFF and APRIL in rheumatoid arthritis. J Cell Physiol, 2019; 234(10):17050–17063; doi: 10.1002/jcp.28445
90.
ShinkawaT, NakamuraK, YamaneN, et al.The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem, 2003; 278(5):3466–3473; doi: 10.1074/jbc.M210665200
91.
ShkunnikovaS, MijakovacA, SironicL, et al.IgG glycans in health and disease: Prediction, intervention, prognosis, and therapy. Biotechnol Adv, 2023; 67:108169; doi: 10.1016/j.biotechadv.2023.108169
92.
TangP, WangJM. Chemokines: The past, the present and the future. Cell Mol Immunol, 2018; 15(4):295–298; doi: 10.1038/cmi.2018.9
93.
TrastoyB, DuJJ, CifuenteJO, et al.Mechanism of antibody-specific deglycosylation and immune evasion by streptococcal IgG-specific endoglycosidases. Nat Commun, 2023; 14(1):1705; doi: 10.1038/s41467-023-37215-3
94.
TroelsenLN, JacobsenS, AbrahamsJL, et al.IgG glycosylation changes and MBL2 polymorphisms: Associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis. J Rheumatol, 2012; 39(3):463–469; doi: 10.3899/jrheum.110584
95.
UllahMA, MackayF. The BAFF-APRIL system in cancer. Cancers (Basel), 2023; 15(6); doi: 10.3390/cancers15061791
96.
VáradiC, HollóZ, PóliskaS, et al.Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF-α treatment responders in inflammatory diseases. Electrophoresis, 2015; 36(11–12):1330–1335; doi: 10.1002/elps.201400575
97.
VincentFB, MorandEF, SchneiderP, et al.The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol, 2014; 10(6):365–373; doi: 10.1038/nrrheum.2014.33
98.
WalterMR. The role of structure in the biology of interferon signaling. Front Immunol, 2020; 11:606489; doi: 10.3389/fimmu.2020.606489
99.
WangW. Glycomedicine: The current state of the art. Engineering, 2023; 26:12–15; doi: 10.1016/j.eng.2022.03.009
100.
WangJ, BalogCIA, StavenhagenK, et al.Fc-Glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics, 2011; 10(5):M110.004655; doi: 10.1074/mcp.M110.004655
101.
WangM, ChenX, TangZ, et al.Association between immunoglobulin G N-Glycosylation and vascular cognitive impairment in a sample with atherosclerosis: A case-control study. Front Aging Neurosci, 2022; 14:823468; doi: 10.3389/fnagi.2022.823468
102.
WangZ, ZhuJ, LuH. Antibody glycosylation: Impact on antibody drug characteristics and quality control. Appl Microbiol Biotechnol, 2020; 104(5):1905–1914; doi: 10.1007/s00253-020-10368-7
103.
WeiQ, LiaoJ, JiangM, et al.Relationship between Th17-mediated immunity and airway inflammation in childhood neutrophilic asthma. Allergy Asthma Clin Immunol, 2021; 17(1):4; doi: 10.1186/s13223-020-00504-3
104.
WuhrerM, StamJC, Van De GeijnFE, et al.Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics, 2007; 7(22):4070–4081; doi: 10.1002/pmic.200700289
105.
ZhangZJ, WangHF, LianTY, et al.Human plasma IgG N -glycome profiles reveal a proinflammatory phenotype in chronic thromboembolic pulmonary hypertension. Hypertension, 2023; 80(9):1929–1939; doi: 10.1161/HYPERTENSIONAHA.123.21408
106.
ZhuW, HeX, ChengK, et al.Ankylosing spondylitis: Etiology, pathogenesis, and treatments. Bone Res, 2019; 7(1):22; doi: 10.1038/s41413-019-0057-8
107.
ZouG, OchiaiH, HuangW, et al.Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor. J Am Chem Soc, 2011; 133(46):18975–18991; doi: 10.1021/ja208390n
